Brief: Biophytis Receives EUR 980,000 DeepTech Funding
29/04/2021 07:09
April 29 (Reuters) - Biophytis SA ALBPS.PA :
* BIOPHYTIS RECEIVES €980,000 DEEPTECH FUNDING FROM BPI
FRANCE FOR
THE DEVELOPMENT OF MACUNEOS (BIO201) IN DRY AMD
* FUNDING CONSISTS OF A CONDITIONAL ADVANCE OF EUR 600,000
AND A
GRANT OF EUR 380,000
* PLANS TO INITIATE A PHASE 1 CLINICAL TRIAL (MACA-PK) IN
HEALTHY
VOLUNTEERS IN SECOND HALF OF 2021
Source text for Eikon: ID:nGNX2QpHJd
Further company coverage: ALBPS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Biophytis SA
See all newsBrief: Biophytis SA Secures $20 Mln For Launch Of Phase 3 Trial In Sarcopenia
Brief: Biophytis Secures Public Funding In Brazil For Obesity Phase 2 Trial
Brief: Biophytis SA Gets EMA Authorization For Phase 2 Clinical Trial In Obesity
Brief: Biophytis Gets EMA & Belgian Regulatory Approval For Phase 3 Sarcopenia Clinical Trial
Brief: Biophytis To Initiate Phase 2 Study In Obesity & Phase 3 Study In Sarcopenia Soon